Forteo (teriparatide) is a brand-name medication that doctors may prescribe to treat osteoporosis. The drug uses proteins to enhance bone strength and promote the development of new bone tissue. You ...

INDIANAPOLIS, May 29, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new data showing that FORTEO significantly increased lumbar spine volumetric bone mineral density (vBMD) ...

SAN DIEGO, Sept. 19, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today presented data comparing the mechanisms of action of FORTEO® (teriparatide [rDNA origin] injection) and zoledronic ...

PARSIPPANY, N.J. & TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceuticals Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the approval of a ...

Ambio announced that a generic version of Forteo (teriparatide injection) developed by Ambio and to be marketed and sold by Apotex has been approved by the Food and Drug Administration. Forteo ...

SAN DIEGO, Sept. 19, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today presented a study that assessed the effects of 18 months of treatment with FORTEO ® (teriparatide [rDNA origin] ...

Teva Pharmaceuticals has received the Food and Drug Administration’s approval for generic Forteo. The product is expected to be available in the coming weeks. “We are thrilled to receive the ...

TEL AVIV, June 15, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) ("Entera" or the "Company"), a leader in the development of oral peptides, today reported comparative Phase 1 data evaluating ...

(RTTNews) - Teva Pharmaceuticals Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced Friday the approval of a generic version of Forteo in the United States. Forteo had ...

Forteo (teriparatide) is a brand-name drug that doctors prescribe for some people with osteoporosis. It contains proteins that strengthen bones and stimulate new bone growth. A typical prescription is ...

today announced new data showing that FORTEO significantly increased lumbar spine volumetric bone mineral density (vBMD) compared to risedronate in men with glucocorticoid-induced osteoporosis.